Starpharma Holdings Limited (SPHRF) Price & Analysis

12 Followers

SPHRF Stock Chart & Stats

$0.21

>-$0.01(-3.96%)

At close: Jan 02 4:00 PM EST

$0.21

>-$0.01(-3.96%)

Day’s Range― - ―

52-Week Range$0.06 - $0.58

Previous CloseN/A

Volume1.00K

Average Volume (3M)3.00

Market Cap

$214.45M

Enterprise Value$281.40M

Total Cash (Recent Filing)$18.25M

Total Debt (Recent Filing)$790.00K

Price to Earnings (P/E)―

Beta0.37

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding420,928,440

10 Day Avg. Volume10

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)1.93

Price to Sales (P/S)7.47

P/FCF Ratio-5.40

Enterprise Value/Market Cap1.31

Enterprise Value/Revenue19.74

Enterprise Value/Gross Profit32.84

Enterprise Value/Ebitda-35.16

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)$16.54M

Bulls Say, Bears Say

Bulls Say

Proprietary Dendrimer PlatformStarpharma’s proprietary dendrimer platform is a durable competitive asset enabling multiple applications (drug delivery, anti-infective, topical). A platform supports licensing, recurring partner revenue, and product diversification, creating long-term optionality beyond single-product risk.

Consistent Revenue GrowthSustained revenue growth indicates expanding adoption or commercial traction for Starpharma’s products and partnerships. Over months this trend helps scale operations, validate the platform to partners, and improves prospects for milestone/royalty flows that underpin durable top-line expansion.

Conservative LeverageLow debt levels provide financial flexibility, reducing refinancing and distress risk. For a biotech investing in R&D and commercialization, conservative leverage supports sustained investment without immediate solvency pressure and makes future collaboration or capital raises less dilutive under stress.

Bears Say

Negative Operating & Free Cash FlowPersistent negative operating and free cash flows signal ongoing cash burn that can force recurrent fundraising. Over a multi-month horizon this constrains investment in trials or commercialization, risks dilution, and limits the company’s ability to self-fund growth or respond to partner opportunities.

Ongoing Unprofitable OperationsNegative EBIT and net margins reflect structural profitability challenges. Without clear margin improvement, the business will struggle to convert revenue into sustainable earnings, reducing internal cash generation and the capacity to reinvest in R&D or scale commercial operations long term.

Negative Return On EquityA negative ROE indicates the company is not generating acceptable returns on invested capital. This undermines investor confidence and may raise the cost of future capital, making it harder to fund development programs or commercial expansion without dilutive financing.

Starpharma Holdings Limited News

Starpharma Hits DEP® Milestone, Opens Licensing Path With Radiopharm

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an announcement. Starpharma has reached a key milestone in its...

4d ago

Starpharma Wins FDA Backing for DEP HER2 Trial as Partnerships and Product Sales Advance

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an update. Starpharma reported strong operational momentum in the March...

2M ago

Starpharma Secures FDA Backing for DEP HER2 First-in-Human Trial Pathway

Starpharma Holdings Limited ( ($AU:SPL) ) has issued an update. Starpharma has received positive guidance from the U.S....

3M ago

Starpharma Seeks ASX Quotation for Over 1 Million New Shares

An update from Starpharma Holdings Limited ( ($AU:SPL) ) is now available. Starpharma Holdings Limited has applied to...

3M ago

UBS Group Ceases to Be Substantial Shareholder in Starpharma

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. UBS Group AG and its related bodies corporate...

4M ago

Starpharma Ramps Up DEP® Partnerships and Radiopharma Pipeline as Viraleze™ Sales Surge

Starpharma Holdings Limited ( ($AU:SPL) ) has issued an announcement. Starpharma reported a highly active second quarter of...

5M ago

Starpharma Seeks ASX Quotation for 1.69 Million New Ordinary Shares

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has applied to...

6M ago

Starpharma Announces Lapse of 381,810 Performance Rights

Starpharma Holdings Limited ( ($AU:SPL) ) just unveiled an update. Starpharma Holdings Limited has notified the market that...

6M ago

Starpharma CEO Receives New Performance Rights

Starpharma Holdings Limited ( ($AU:SPL) ) has provided an announcement. Starpharma Holdings Limited announced a change in the...

7M ago

Starpharma Issues Unquoted Securities to Boost Employee Incentives

The latest update is out from Starpharma Holdings Limited ( ($AU:SPL) ). Starpharma Holdings Limited has announced the...

7M ago

SPHRF FAQ

What was Starpharma Holdings Limited’s price range in the past 12 months?

Starpharma Holdings Limited lowest stock price was $0.06 and its highest was $0.58 in the past 12 months.

What is Starpharma Holdings Limited’s market cap?

Starpharma Holdings Limited’s market cap is $214.45M.

When is Starpharma Holdings Limited’s upcoming earnings report date?

Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 51 days.

How were Starpharma Holdings Limited’s earnings last quarter?

Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported $0.002 earnings per share for the quarter, beating the consensus estimate of N/A by $0.002.

Is Starpharma Holdings Limited overvalued?

According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Starpharma Holdings Limited pay dividends?

Starpharma Holdings Limited does not currently pay dividends.

What is Starpharma Holdings Limited’s EPS estimate?

Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Starpharma Holdings Limited have?

Starpharma Holdings Limited has 420,928,440 shares outstanding.

What happened to Starpharma Holdings Limited’s price movement after its last earnings report?

Starpharma Holdings Limited reported an EPS of $0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Starpharma Holdings Limited?

Currently, no hedge funds are holding shares in SPHRF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Starpharma Holdings Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-15.96%

Trailing 12-Months

Asset Growth

-4.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Starpharma Holdings Limited

Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.